Goldstone Lisa W
Titus Family Department of Clinical Pharmacy, University of Southern California, Los Angeles, CA. Email:
Am J Manag Care. 2020 Mar;26(3 Suppl):S48-S54. doi: 10.37765/ajmc.2020.43011.
Schizophrenia is a chronic mental health disorder hallmarked by a variety of symptoms impacting mental state, emotions, and behaviors, including delusions, hallucinations, disorganized speech, grossly disorganized or catatonic behavior, negative symptoms, and cognitive impairment. Schizophrenia leaves patients with the inability to function appropriately in their daily lives, including at work, in relationships, and even with self-care. The exact cause of this disorder has yet to be elucidated; however, multiple factors, including genetic susceptibility and environmental influences, have been implicated in its development. Patients with schizophrenia frequently demonstrate medication nonadherence and have multiple concurrent comorbidities that lead to increased morbidity and mortality. Schizophrenia is estimated to affect more than 21 million individuals globally, and while many therapies have become available for management, the disorder still presents unique challenges to providers, caregivers, and the healthcare system. Unmet medical needs remain for this complex disease state, and research is ongoing to address these needs and improve the overall health and outcomes of patients living with schizophrenia.
精神分裂症是一种慢性心理健康障碍，其特征是多种影响精神状态、情绪和行为的症状，包括妄想、幻觉、言语紊乱、严重的行为紊乱或紧张症行为、阴性症状和认知障碍。精神分裂症使患者在日常生活中无法正常发挥功能，包括在工作、人际关系甚至自我照顾方面。这种疾病的确切病因尚未阐明；然而，多种因素，包括遗传易感性和环境影响，都与它的发展有关。精神分裂症患者经常表现出药物治疗依从性差，并且有多种并发疾病，这导致发病率和死亡率增加。据估计，全球有超过2100万人受到精神分裂症的影响，虽然有许多治疗方法可用于管理，但这种疾病仍然给医疗服务提供者、护理人员和医疗保健系统带来独特的挑战。对于这种复杂的疾病状态，尚未满足的医疗需求仍然存在，目前正在进行研究以满足这些需求，并改善精神分裂症患者的整体健康状况和治疗结果。
